Announcement PDF ASX: SPL US OTC: SPHRY Starpharma Announces Collaboration and License Agreement with Genentech Shareholder Presentation 22 September 2025 Executive Summary • Starpharma has signed a collaboration and license agreement with Genentech, a member of the Roche Group. • Starpharma will employ its proprietary DEP® platform technology to develop dendrimerdrug conjugates that incorporate Genentech medicines for certain oncology targets. • Starpharma will receive an upfront payment of USD $5.5 million (~AUD $8.3 million). • Starpharma is eligible to receive up to USD $564 million (~AUD $855 million) in successbased development, regulatory, and commercial milestones. • In addition to this amount, Starpharma is eligible for tiered royalties on global net sales of products resulting from the collaboration. About Starpharma Starpharma is an Australian biotechnology company with over 20 years of experience in advancing dendrimer technology from the lab to the patient Clinically validated DEP® platform technology Leadership in dendrimer science and drug development More than 350 patients treated with DEP® across multiple clinical oncology programs. 20 years of dendrimer innovation, science & pharmaceutical development. Broad technology application Strategic global partnerships Versatile and scalable technology, supporting applications in oncology, radiotheranostics, and more. High-impact partnerships with global leaders, leveraging Starpharma’s DEP® platform to expand commercial opportunities. About Genentech Considered the founder of the biotech industry and now a member of the Roche Group, Genentech has been delivering on the promise of biotechnology for nearly 50 years Pioneering pharmaceutical innovation A community of changemakers Discovered the first targeted antibody for cancer and the first medicine for primary progressive multiple sclerosis. Nearly 50 years of working to solve unmet medical needs. Staff of 11.9K people. Partnering to solve complex health challenges Strong product pipeline 250+ ongoing collaborations around the world. Around 70 new investigational medicines in clinical development and over 270 active clinical trials in the United States. Collaboration Overview Starpharma will employ its proprietary DEP® platform technology to develop dendrimer-drug conjugates that incorporate Genentech medicines for certain oncology targets. Genentech has an exclusive worldwide license under Starpharma’s IP to commercialize products resulting from the parties’ collaboration. Genentech will be responsible for all development and commercialization of products resulting from the collaboration, which could include multiple products for each target. Financial Terms Upfront payment USD $5.5 million (~AUD $8.3 million) Success-based milestones Up to USD $564 million (~AUD $855 million) Starpharma is also eligible for tiered royalties on global net sales of products resulting from the collaboration. Strategic Significance for Starpharma Recognises the potential of Starpharma’s dendrimer technology in drug delivery innovation Demonstrates the opportunities presented by research partnerships Marks important progress against our strategic plan Thank you. Investor Hub Corporate Office investors.starpharma.com 4 – 6 Southampton Crescent Abbotsford, Victoria 3067 Australia